SCHEMBL5453931

SCHEMBL5453931

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4ccc(C(F)(F)F)c(F)c4)cc3)cc2CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KIF11 P52732 3/20 0.35
PTGS2 P35354 2/20 0.35
P2RX7 Q99572 1/20 0.35
NR1H2 P55055 3/20 0.33
NR1H3 Q13133 2/20 0.33
PTGS1 P23219 1/20 0.33
SFRP1 Q8N474 2/20 0.33
WNT3 P56703 1/20 0.33
MOGAT2 Q3SYC2 3/20 0.32
HTR2A P28223 3/20 0.32
HTR2C P28335 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
DRD2 P14416 1/20 0.32
CYP2C19 P33261 1/20 0.32
DRD3 P35462 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459290 0.92 USP2 (0.36) USP2SMN1; SMN2P2RX7HTR2AHTR2C
SCHEMBL5448741 0.89 USP2 (0.39) USP2SMN1; SMN2MOGAT2HTR2AHTR2C
SCHEMBL5450383 0.89 UTS2R (0.38) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5449066 0.88 PYCR1 (0.38) USP2SMN1; SMN2PTGS2POLB
SCHEMBL5444653 0.88 HTR2A (0.34) USP2SMN1; SMN2SFRP1WNT3MOGAT2
SCHEMBL5457137 0.87 USP2 (0.38) USP2SMN1; SMN2MOGAT2HTR2AHTR2C
SCHEMBL5445721 0.86 USP2 (0.41) USP2SMN1; SMN2MOGAT2HTR2AHTR2C
SCHEMBL5462437 0.85 KMT2A (0.38) USP2SMN1; SMN2HTR2AHTR2CCYP1A2
SCHEMBL5448944 0.85 HTR2A (0.36) USP2SMN1; SMN2P2RX7MOGAT2HTR2A
SCHEMBL5451428 0.85 GALR3 (0.42) USP2SMN1; SMN2HTR2AHTR2CHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 USP2 4595/4885SMN1; SMN2 2075/4885KIF11 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.